patient compliance with their new protease inhibitor, Norvir (ritonavir)
June 1996
Abbott is sending out letters emphasizing patient compliance with their new protease inhibitor, Norvir (ritonavir).
The problem is that patients starting Norvir often develop nausea...diarrhea...and numbness and tingling. This may tempt them to stop the drug or cut back on the dose.
But maintaining therapeutic levels of Norvir is crucial...to suppress HIV and prevent the development of resistance.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote